Muat turun App untuk nikmati tawaran istimewa
  1. Laman utama
  2. Jepun
  3. Kyushu
  4. Oita
  5. Takeda

Takeda

Maklumat pelancongan

Takeda 10 pengalaman dan tarikan yang mesti dicuba

Takeda aktiviti dan tawaran terkini

Takeda cuaca, iklim dan musim perjalanan terbaik

Sumber data：Meteostat
Tarikh dikemas kini：2025-09

Takeda iklim sepanjang tahun

  • Spring (March–May): Average 10.5–19.3°C, mild climate but with more rainfall, especially in April and May. Common activities: Spring outings, flower viewing. Recommended clothing: Light jacket, long-sleeved shirt, and rain gear.
  • Summer (June–August): Average 23.7–29.5°C, hot and humid with abundant rainfall. Common activities: Summer resorts, water activities (if facilities are available). Recommended clothing: Light and breathable clothing, short sleeves, and shorts, and rain gear.
  • Autumn (September–November): Average 19.1–27.1°C, comfortable and pleasant climate with gradually decreasing rainfall. Common activities: Maple viewing (if maple leaves are present), outdoor excursions. Recommended clothing: Long-sleeved shirt, light jacket.
  • Winter (December–February): Average 5.1–7.2°C, cold and dry with the least rainfall. Common activities: Hot spring trips (if facilities are available), indoor activities. Recommended clothing: Warm coat, sweater, scarf, gloves.

Takeda purata iklim

Annual average temperature: approx. 17.2°C / Annual rainfall: approx. 1598 mm / Summer humidity: 70%–80% / Rainiest month: August

Suhu purata dan kerpasan bulan Takeda

Bulan
Suhu (°C)
Curahan hujan (mm)
Januari
5.1°C
47.4
Februari
6.1°C
53.8
Mac
10.5°C
115.7
April
16.4°C
158.9
Mei
19.3°C
199.8
Jun
23.7°C
248.8
Julai
28.9°C
176
Ogos
29.5°C
254.7
September
27.1°C
127.3
Oktober
19.1°C
105.2
November
13.9°C
91.9
Disember
7.2°C
19.2

Cuaca Takeda untuk tujuh hari akan datang

11/8
Ahad
Overcast
15.1°C/8.2°C
11/9
Isnin
Overcast
15.6°C/9.7°C
11/10
Selasa
Sunny
13.5°C/7.8°C
11/11
Rabu
Sunny
16.5°C/4.5°C
11/12
Khamis
Sunny
17.7°C/5.3°C
11/13
Jumaat
Partly Cloudy
19.1°C/6.5°C
11/14
Sabtu
Cloudy
19.7°C/7.8°C

Takeda Soalan Lazim & Maklumat Berguna Pelancongan

What is Takeda pharmaceutical company known for?

Takeda is known as a global pharmaceutical company that develops life-transforming medicines and therapies in its focus areas of oncology, rare diseases, gastroenterology, neuroscience, plasma-derived therapies, and vaccines. With a history dating back over 200 years, Takeda is recognized for its strong focus on research and development, strategic acquisitions like the takeover of Shire Plc, and its efforts to improve access to medicine and health care in emerging markets. Takeda is a research-driven biopharmaceutical company, heavily investing in R&D to discover and deliver innovative treatments. The company's R&D efforts focus on specific areas to cultivate expertise and accelerate the development of life-transforming medicines for patients.

What are Takeda's key therapeutic areas?

Takeda's key therapeutic areas of focus include oncology, rare diseases, gastroenterology, neuroscience, plasma-derived therapies, and vaccines.

Is Takeda a large pharmaceutical company?

Yes, Takeda is considered a 'big pharma' company. It is Japan's largest drugmaker and one of the top pharmaceutical companies in the world by revenue, a ranking that rose significantly following its merger with Shire. Takeda is a leading global biopharmaceutical company with a significant presence worldwide. The company's substantial acquisition of Shire was a major move that increased its size and global impact. Takeda invests heavily in research and development and is known for developing life-transforming treatments.

What is Takeda's top-selling drug?

Entyvio is frequently cited as Takeda's top-selling drug. It is a biologic therapy primarily used for the treatment of inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease.

Why did Takeda restructure its programs?

Amid a broader profit decline catalyzed by patent losses, Takeda restructured. In the process, the company cut a series of programs for solid tumors and blood cancers and pivoted to autoimmune conditions, as many other cell therapy developers have amid a tough funding climate.